UCB (LTS:0NZT) Total Liabilities : €6,564 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is UCB Total Liabilities?

UCB's Total Liabilities for the quarter that ended in Dec. 2023 was €6,564 Mil.

UCB's quarterly Total Liabilities declined from Dec. 2022 (€6,804.00 Mil) to Jun. 2023 (€6,339.00 Mil) but then increased from Jun. 2023 (€6,339.00 Mil) to Dec. 2023 (€6,564.00 Mil).

UCB's annual Total Liabilities increased from Dec. 2021 (€5,824.00 Mil) to Dec. 2022 (€6,804.00 Mil) but then declined from Dec. 2022 (€6,804.00 Mil) to Dec. 2023 (€6,564.00 Mil).

UCB Total Liabilities Historical Data

The historical data trend for UCB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB Total Liabilities Chart

UCB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

4,072.00

6,047.00

5,824.00

6,804.00

6,564.00

UCB Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															5,824.00	7,391.00	6,804.00	6,339.00	6,564.00

UCB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

UCB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2616	+	(2996	+	725
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	227)
	=	6,564

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	15539	-	8975
	=	6,564

UCB's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2616	+	(2996	+	725
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	227)
	=	6,564

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	15539	-	8975
	=	6,564

UCB Total Liabilities Related Terms

Thank you for viewing the detailed overview of UCB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB (LTS:0NZT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (LTS:0NZT) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

UCBJY:USA UCBJF:USA UCBb:UK UNC:Germany UCB:Belgium UCB:Austria

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (LTS:0NZT) Headlines

No Headlines